Eli Lilly Shares Ajax Acquisition Data Showing Myelofibrosis Drug Candidate
Eli Lilly released initial clinical results from its acquisition of Ajax Therapeutics on June 15, 2026. The data position the program as a potential competitor to existing myelofibrosis treatments.
dutchnews.nlEli Lilly released the first clinical data from its acquisition of Ajax Therapeutics on June 15, 2026. The results present a candidate positioned against current myelofibrosis therapies. 3 billion, brought Ajax's myelofibrosis program into Lilly's pipeline.
The newly disclosed data form the initial public readout supporting that deal. A separate development involves Sanofi's diabetes drug Tzield. The FDA approved the treatment following a review process described as unusually contentious.
Shortages have also affected Pfizer's injectable penicillin product Bicillin. An Arizona woman was unable to receive timely treatment for syphilis during pregnancy because of the supply constraints. The Trump administration has proposed closing a Medicare negotiation loophole, according to the same reporting.
